Recently, immune checkpoint inhibitors, particularly anti-PD-1/PD-L1 agents such as nivolumab and pembrolizumab, have shown promise in reactivating the immune system to target and eliminate tumor cells of HNSCC [2,3]. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.